Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pibizyme is a digestive enzyme combination product manufactured by P.B. Pharmaceuticals, primarily marketed in regions such as Ghana. It is formulated as an oral liquid (syrup) containing fungal diastase and pepsin. Fungal diastase, derived from *Aspergillus oryzae*, acts as an amylolytic enzyme that facilitates the breakdown of complex carbohydrates (starch) into simpler sugars. Pepsin is a proteolytic enzyme that aids in the digestion of dietary proteins by cleaving them into smaller peptides. Pibizyme is indicated for the management of digestive disorders, including acid indigestion, flatulence, dyspepsia, and epigastric distress, particularly when these conditions are associated with impaired enzyme secretion or heavy meals.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fungal diastase + pepsin.